Octamer-binding transcription factor 4, a key factor in maintaining stem cell properties in tumor cells, can be reversed by JMJD3 in breast cancer, and the vitamin D receptor agonist paricalcitol has been shown to modulate breast cancer malignancy by activating the inhibitory effects of JMJD3 on octamer-binding transcription factor 4 [139]. This evidence concerns the gene KDM6B and breast cancer.